What is Genetic Technologies Price-to-Operating-Cash-Flow?
As of today (2024-12-11), Genetic Technologies's share price is €0.049.
Genetic Technologies's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jun. 2024 was €-0.03. Hence, Genetic Technologies's Price-to-Operating-Cash-Flow Ratio for today is .
The historical rank and industry rank for Genetic Technologies's Price-to-Operating-Cash-Flow or its related term are showing as below:
During the past 13 years, Genetic Technologies's highest Price-to-Operating-Cash-Flow Ratio was 24.00. The lowest was 0.00. And the median was 23.00.
Genetic Technologies's Cash Flow from Operations per share for the
three
months ended in Jun. 2024 was €-0.01.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jun. 2024 was €-0.03.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 0.50% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 18.10% per year.
During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 26.50% per year.
During the past 13 years, Genetic Technologies's highest 3-Year average Operating Cash Flow per Share Growth Rate was 67.80% per year. The lowest was -120.40% per year. And the median was 18.20% per year.
Genetic Technologies Price-to-Operating-Cash-Flow Historical Data
The historical data trend for Genetic Technologies's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genetic Technologies Price-to-Operating-Cash-Flow Chart
|
Genetic Technologies Annual Data
|
|
Trend |
Jun15 |
Jun16 |
Jun17 |
Jun18 |
Jun19 |
Jun20 |
Jun21 |
Jun22 |
Jun23 |
Jun24 |
| Price-to-Operating-Cash-Flow |
|
Get a 7-Day Free Trial
|
|
|
- |
- |
- |
- |
- |
|
Genetic Technologies Quarterly Data
|
|
Jun19 |
Dec19 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
Jun24 |
Sep24 |
| Price-to-Operating-Cash-Flow |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
- |
- |
- |
- |
- |
Competitive Comparison of Genetic Technologies's Price-to-Operating-Cash-Flow
For the Diagnostics & Research subindustry, Genetic Technologies's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genetic Technologies's Price-to-Operating-Cash-Flow Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Technologies's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Genetic Technologies's Price-to-Operating-Cash-Flow falls into.
Genetic Technologies Price-to-Operating-Cash-Flow Calculation
Genetic Technologies's Price-to-Operating-Cash-Flow ratio for today is calculated as
| Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
| = | 0.049 | / | -0.031 |
| = | |
Genetic Technologies's Share Price of today is €0.049.
Genetic Technologies's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.03.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
Genetic Technologies Business Description
Traded in Other Exchanges
Address
60-66 Hanover Street, Fitzroy, Melbourne, VIC, AUS, 3065
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.
Genetic Technologies Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:DU8 has been successfully added to your